Navigation Links
Gated STED -- developing the next generation of super-resolution microscopes
Date:11/11/2011

This release is available in German.

Leica Microsystems has signed an agreement with the Max Planck Society and the German Cancer Research Center (DKFZ) for the development of the next generation of super-resolution STED (Stimulated Emission Depletion) microscopy. This gives Leica Microsystems the license to develop the new technology, called gated STED, into a commercial product and put it on the market.

Stefan Hell, Director at the Max Planck Institute for Biophysical Chemistry, has taken his idea of STED microscopy a momentous step further with gated STED: The new technology significantly improves the resolution and contrast previously attained with CW-STED (Continuous-Wave Stimulated Emission Depletion) microscopy, while distinctly reducing laser intensity. This enhances photostability as well as live cell capability, substantially extending the range of possible applications. Also, gated STED technology will considerably increase the number of issues that can be addressed with STED fluorescence correlation spectroscopy (STED-FCS). The main application of gated STED technology will be the observation of molecule movements in the membrane of living cells.

The new product of Leica Microsystems will be launched in the first half of the year 2012. Thanks to Leica Microsystems' modular concept, the Leica TCS SP5 and Leica TCS STED CW confocal systems already on the market can be upgraded with gated STED.

"We're delighted to be able to continue the provenly successful cooperation with the Max Planck Society, its technology transfer organization Max Planck Innovation and the DKFZ with this trailblazing product development," says Stefan Traeger, Vice President of Leica Microsystems' Life Science Division. "The new gated STED microscope will enable us to further strengthen our technological lead in super-resolution microscopy especially for confocal systems."


'/>"/>
Contact: Markus Berninger
Markus.Berninger@Max-Planck-Innovation.de
49-892-909-1930
Max-Planck-Gesellschaft
Source:Eurekalert  

Related biology technology :

1. Retrospective Analysis of Phase 3 Data Suggest Wyeths Investigational Compound Bazedoxifene/Conjugated Estrogens Comparable to Placebo on Incidence of Abnormal Mammograms
2. Transgenomic Awarded SBIR Grant to Support Development of SURVEYOR(R) Endonuclease Adaptor-ligated Libraries (SEAL) for Determining Whole Genome Sequence Variation
3. As personalized, genomic medicine takes off, four developing countries show the way for others
4. Napo Pharmaceuticals Will Provide Pediatric Formulation of Crofelemer at Cost to Developing Nations to Help Treat Life-Threatening Diarrhoel Diseases (Subject to FDA Approval)
5. BIO Ventures for Global Health Receives $7 Million Grant from Gates Foundation to Engage Biotechnology in the Fight Against Neglected Diseases of the Developing World
6. Frost & Sullivan Acknowledges ISTO Technologies Role in Developing Advanced Biologic Products for Bone Healing
7. MaxCyte Hosts Live Discussion with Industry Experts on the Challenges in Developing Cell-Based Screening Assays for Drug Discovery
8. Frost & Sullivan Recognizes ESBATechs Innovation in Developing Antibody Fragments for Biologic Therapeutics
9. Developing a Safer and More Effective Way to Deliver Rabies Antibodies
10. Schering-Plough Announces Collaboration With World Health Organization to Provide Access to Pandemic Influenza Vaccine Technology to Developing Countries
11. Immtech and Beijing Pharmaceutical Group Co. Sign Memorandum of Understanding to Explore Developing Strategic Business Alliance
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Gated STED -- developing the next generation of super-resolution microscopes
(Date:3/23/2017)... , March 23, 2017 In ... four equities in the Biotech industry: Sangamo Therapeutics Inc. ... Inc. (NYSE MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... , 2017, Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from ... their free report at: ...
(Date:3/22/2017)... March 22, 2017  Ascendis Pharma A/S (Nasdaq: ... TransCon technology to address significant unmet medical needs ... the full year ended December 31, 2016. ... our company as we broadened our pipeline and ... rare disease company with an initial focus on ...
(Date:3/22/2017)... LEXINGTON, Mass. , March 22, 2017   ... collections, today announced that Doctors Pathology Service ... mid-Atlantic region of the United States ... the Delaware Health Information Network (DHIN) to ... researchers. The novel program, announced in ...
(Date:3/22/2017)... 22, 2017   Boston Biomedical , an industry ... to target cancer stemness pathways, today announced its Board ... as Chief Executive Officer, effective April 24, 2017. ... Li , M.D., FACP, who has led Boston Biomedical ... his leadership, Boston Biomedical has grown from a "garage ...
Breaking Biology Technology:
(Date:3/2/2017)... , March 2, 2017 Australian stem cell ... (ASX: CYP), has signed an agreement with the Monash ... Monash Biomedicine Discovery Institute and Department of Pharmacology at ... a further preclinical study to support the use of ... asthma.  Asthma is a chronic, long ...
(Date:2/28/2017)... , February 28, 2017 News solutions for ... ... from 14 to 16 March, Materna will present ... show how seamless travel is a real benefit for passengers. ... biometrics to their passenger touch point solutions to take passengers through ...
(Date:2/26/2017)... Feb. 25, 2017  Securus Technologies, a leading ... for public safety, investigation, corrections and monitoring, announces ... Reentry. "Too often, too many offenders ... county jails are trying to tackle this ongoing ... friends and family members. While significant steps are underway, ...
Breaking Biology News(10 mins):